Recruiting Phase 1

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

Condition: Metastatic Castration-resistant Prostate Cancer
Tested: BMS-986460
Sponsor: Bristol-Myers Squibb

Who can join

Age: 18 years and older
Sex: Male only
Healthy volunteers: Not accepted

Inclusion 7

Minimum age: 18 years
Eligible sex: Male
Study condition: Metastatic Castration-resistant Prostate Cancer
Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.
Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)

Exclusion 4

Participant must not have history of brain metastases.
Participant must not have impaired cardiac function or clinically significant cardiac disease.
Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.
Other protocol-defined inclusion/exclusion criteria apply

Where

15 sites, 14 recruiting

Centre Leon Berard

Lyon Cedex08, Auvergne-Rhône-Alpes, France

Recruiting

Institut Paoli-Calmettes

Marseille, Nan, France

Recruiting

Gustave Roussy

Villejuif, Val-de-Marne, France

Recruiting

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Recruiting

Duke Cancer Institute

Durham, North Carolina, United States

Recruiting

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Recruiting

and 9 more sites on ClinicalTrials.gov

Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.

Potential match only. Final eligibility is determined by the study team.